About: Pharmacologic therapeutic options for thromboprophylaxis in COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacologic therapeutic options for thromboprophylaxis in COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pharmacologic therapeutic options for thromboprophylaxis in COVID-19
Creator	Hasan, Shahzad Kow, Chia Syed, ·
Source	Medline; PMC
abstract	covid:280aa487f8144f85424d59728d16ad39fe78e5e8#abstract
has issue date	2020-06-28(xsd:dateTime)
bibo:doi	10.1007/s11239-020-02200-w
bibo:pmid	32596786
has license	no-cc
sha1sum (hex)	280aa487f8144f85424d59728d16ad39fe78e5e8
schema:url	https://doi.org/10.1007/s11239-020-02200-w
resource representing a document's title	Pharmacologic therapeutic options for thromboprophylaxis in COVID-19
has PubMed Central identifier	PMC7321015
has PubMed identifier	32596786
schema:publication	J Thromb Thrombolysis
resource representing a document's body	covid:280aa487f8144f85424d59728d16ad39fe78e5e8#body_text
is schema:about of	named entity 'COVID-19' named entity 'tailored' named entity 'coagulopathy' named entity 'AMID' named entity 'hospitalized' named entity 'VTE' named entity 'patients' named entity 'critically ill' named entity 'coagulopathy' named entity 'thromboprophylaxis' named entity 'ritonavir' named entity 'thromboprophylaxis' named entity 'rivaroxaban' named entity 'COVID-19' named entity 'enoxaparin' named entity 'thromboprophylaxis' named entity 'intensive care units' named entity 'Factor Xa' named entity 'relative risk' named entity 'rivaroxaban' named entity 'prophylaxis' named entity 'infectious diseases' named entity 'invasive procedures' named entity '95% confidence interval' named entity 'factor Xa inhibitors' named entity 'parenteral' named entity 'VTE' named entity 'subgroup analysis' named entity '95% confidence interval' named entity 'COVID-19' named entity 'thromboprophylaxis' named entity 'major bleeding' named entity 'COVID-19' named entity 'subcutaneous' named entity 'enoxaparin' named entity 'mechanically ventilated' named entity 'thromboprophylaxis' named entity 'CYP3A4' named entity 'clinical trials' named entity 'COVID-19' named entity 'pulmonary infections' named entity 'intubated' named entity 'VTE' named entity 'factor Xa inhibitors' named entity 'enoxaparin' named entity 'rivaroxaban' named entity '0.45' named entity 'heparin' named entity 'relative risk reduction' named entity 'VTE' named entity 'COVID-19 pandemic' named entity 'factor Xa inhibitors' named entity 'enoxaparin' named entity 'enoxaparin' named entity 'bioavailability' named entity 'significant difference' named entity 'SARS-CoV-2' named entity 'enoxaparin' named entity 'COVID-19' named entity 'infectious diseases' named entity 'relative risk' named entity 'subcutaneous' named entity 'observational studies' named entity 'COVID-19' named entity 'subcutaneous administration' named entity 'relative risk' named entity 'prophylaxis' named entity 'protease' named entity 'asymptomatic' named entity 'host cells' named entity 'pharmacological' named entity 'half lives' named entity 'vasopressors' named entity 'rivaroxaban' named entity 'relative risk' named entity 'effect size' named entity 'older age' named entity 'anticoagulants' named entity 'heparin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software